T1	Participants 53 109	type 2 diabetes inadequately controlled on basal insulin
T2	Participants 250 287	basal insulin-treated type 2 diabetes
T4	Participants 551 662	The baseline characteristics were balanced among the groups [mean HbA1c 8.2% (67 mmol/mol), BMI 32.2 kg/m(2) ].
T3	Participants 297 536	Patients inadequately controlled [glycated haemoglobin (HbA1c) >7 to ≤10% (>53 to ≤86 mmol/mol)] on basal insulin (glargine, detemir, NPH) were randomized to empagliflozin 10 mg (n = 169), empagliflozin 25 mg (n = 155) or placebo (n = 170)
